Table 2 (abstract P24). Efficacy ─ 52-week OLE completers
Outcome | Time-point | Erenumab 70-mg (OLE last dose received) (N=266) | Erenumab 140-mg (OLE last dose received) (N=203) |
|---|---|---|---|
Change from baseline in MMD, mean (95% CI) | Baseline | 17.92 (17.38, 18.45) | 17.79 (17.16, 18.43) |
Week 40 | -7.81 (-8.64, -6.97 ) (n=228) | -9.96 (-10.91, -9.00 ) (n=187) | |
Week 52 | -8.49 (-9.35, -7.63) (n=214) | -10.48 (-11.52, -9.43) (n=165) | |
Change from baseline in MSMD, mean (95% CI) | Baseline | 10.22 (9.39, 11.06) | 8.32 (7.28, 9.35) |
Week 40 | -4.68 (-5.33, -4.04) (n=228) | -4.59 (-5.32, -3.85) (n=187) | |
Week 52 | -5.05 (-5.76, -4.34) (n=214) | -4.97 (-5.81, -4.13) (n=165) | |
Change from baseline in MSMD in subjects taking MSM, mean (95% CI) | Baseline | 12.40 (11.67, 13.13) | 11.35 (10.30, 12.40) |
Week 40 | -5.63 (-6.33, -4.93) | -6.15 (-7.00, -5.30) | |
Week 52 | -6.16 (-6.93, -5.40) | -6.71 (-7.67, -5.75) | |
≥50% responder rate, N1(%) | Week 40 | 108 (47.4) (n=228) | 126 (67.4) (n=187) |
Week 52 | 114 (53.3) (n=214) | 111 (67.3) (n=165) |